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Purpose: To explore the effect of the clinical treatment of chronic atro-
phic gastritis Methods: 70 patients with chronic atrophic gastritis treated 
in our hospital from October 2017 to November 2018 were selected and 
randomly divided into an observation group and a control group with 35 
patients in each group. The control group received standard triad treatment 
with gastroprokinetic drug orally. On the basis of the control group, pa-
tients in the observation group received Xianlu Pazhu Wan. The treatment 
ef ciency, eradication rate of helicobacter pylori (H. pylori), incidence of 
adverse effects and length of stay were compared between the two groups. 
Results: Compared with the control group, patients in the observation 
group had higher treatment efficiency, higher H. pylori eradication rate, 
lower incidence of adverse effects, and shorter length of stay with statistical 
significance (P< 0.05). Conclusion: In the clinical treatment of patients 
with chronic atrophic gastritis, adding Xianlu Pazhu Wan into the basic 
medication plan can have better treatment ef ciency, reduce the incidence 
of adverse effects, and shorten the length of stay. Therefore, Xianlu Pazhu 
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hronic atrophic gastritis, a common and frequently 
disease of the digestive system, is a chronic gas-
tric disease in which the amount of mucosal glan-
dular cells decreases or intestinal metaplasia or dysplasia 
occurs on the basis of in ammation of the gastric mucosa. 
This disease commonly develops from non-chronic atro-
phic gastritis caused by H. pylori infection[1]. In addition, 
the onset of gastric cancer is very directly connected to 
chronic atrophic gastritis. In 1978, the World Health Or-
ganization de ned chronic atrophic gastritis as the transi-
tional period before the onset of gastric cancer. Therefore, 
treatment is essential to the chronic atrophic gastritis, and 
can effectively prevent further deterioration and develop-
ment of the disease[2]. Therefore, this study mainly inves-
tigated the clinical treatment of chronic atrophic gastritis. 
The speci c research process and results are as follows. 
2. General Data and Method 
2.1 Clinical Data 
70 patients with chronic atrophic gastritis diagnosed elec-
tronic gastroscopy and pathology, and treated between 
October 2017 and November 2018 in our hospital were 
selected. They were divided into an observation group and 
a control group with 35 patients in each group. The pa-
tients in these two groups were treated with different ther-
apies. There were 20 male and 15 female patients in the 
control group, ranging in age from 25 to 65 years, with an 
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average age of (45.1±19.9) years. The course of disease 
ranged from 6 months to 10 years, with an average dura-
tion of (5.2±1.7) years. There were 23 mild atrophic pa-
tients, 8 moderate atrophic patients, and 4 severe atrophic 
patients. There were 18 male and 17 female patients in 
the observation group, ranging in age from 28 to 71 years, 
with an average age of (46.3±20.1) years. The course of 
disease ranged from 6 months to 10 years, with an aver-
age duration of (4.2±1.5) years. There were 25 mild atro-
phic patients, 5 moderate atrophic patients, and 5 severe 
atrophic patients. The age, gender, course of disease and 
other clinical data of patients in the observation group and 
the control group were compared. The difference was not 
statistically signi cant (P> 0.05) and could be compared 
in groups.
2.2 Disease Diagnosis 
(1) Inclusion criteria: All patients had varying degrees 
of nausea and loss of appetite, and a few of patients had 
anemia, weight loss and other symptoms. The gastroscopy 
showed that the gastric mucosa was thinner and the blood 
vessels beneath the mucosa were exposed. Moreover, after 
the pathological biopsy of gastric mucosa, it was found 
that the gastric mucosa glands of the patients had a ten-
dency of atrophy[3]. 
(2) Exclusion criteria: The patient of drug allergy, func-
tional injury of viscera, mental disorder and malignancy 
excludes completely[4].
2.3 Therapeutic Methods
The control group patients were treated with standard 
triad therapy, which was omeprazole (20mg), amoxicillin 
(1.0g), metronidazole (0.4g) with domperidone 10mg 30 
minutes before meal, three times a day for four continuous 
weeks. The observation group patients were treated on the 
basis of the control group with adding Xianlu Pazhu Wan 
2-2.5g per time, twice a day for 4 continuous weeks. The 
clinical manifestations of patients in two groups were ob-
served[5].
2.4 Ef cacy Evaluation Standard 
The therapeutic effects of the patients were divided into 
obvious, effective and no effect. Obvious referred to the 
patient’s abdominal pain, abdominal distension, nausea 
and other clinical symptoms had completely disappeared, 
and no abnormality was found by gastroscopy; Effective 
referred to the patient’s abdominal pain, abdominal dis-
tension, nausea and other clinical symptoms basically 
disappeared, and a slight abnormality was found by gas-
troscopy; No effect referred to the patient’s abdominal 
distension, abdominal pain, nausea and other clinical 
symptoms not only did not get any relief, there were even 
signs of aggravation. The patient had have dyspepsia, loss 
of appetite and other symptoms. The total effective rate of 
the treatment = (obvious + effective)/total number of the 
patients *100% In addition, the eradication rate of H. py-
lori, incidence of adverse effects and length of stay in the 
two groups should also be observed and calculated.
2.5 Statistical Processing
Statistical software SPSS20 was used to process all the 
data obtained in the research process. Among them, t test 
was used to verify the quantitative data. Percentage was 
used to represent the enumeration data. x2 test was used to 
verify the enumeration data. If P<0.05, the difference was 
statistically signi cant.
3. Results
3.1 Comparison of Treatment Efficiency and H. 
pylori Eradication Rate between the Two Groups
After the two groups of patients were treated with different 
treatment methods, the treatment efficiency and H. pylori 
eradication rate of the two groups were observed, calcu-
lated and compared. The  nal results showed that the total 
treatment ef ciency of the observed patients was 94.29%, 
and the H. pylori eradication rate was 88.57%. However, 
the total treatment ef ciency of the patients in the control 
group was 80.00%, and the H. pylori eradication rate was 
62.86%. This meant that the treatment ef ciency of the ob-
servation group was signi cantly better comparing with the 
control group, which was statistically signi cant (P<0.05). 
The details are shown in Table 1 and 2 below. 
Table 1. Comparison of effective rate of treatment be-
tween the two groups
Ef cacy 







Obvious 26 74.29% 10 28.57%
Effective 7 20.00% 18 51.43%
No effect 2 5.71% 7 20.00%
Total effec-
tive rate 
35 94.29% 35 80.00%










35 31 4 88.57%
Control group 35 22 13 62.86%
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3.2 Comparison of Incidence of Adverse Effects 
between the Two Groups 
After different clinical treatment methods were applied to 
the two groups of patients, it was found that 1 patient in 
the observation group presented vomiting and 1 patient 
presented diarrhea. The total incidence of adverse effects 
was 8.57%. In the control group, 4 patients had vomiting, 
5 patients had diarrhea, and 1 patient had rashes. The total 
incidence of adverse effects was 28.58%. This also indi-
cated that compared with the control group, the incidence 
of adverse effects in the observation group was lower, 
which was statistically signi cant (P< 0.05). The details 
are shown in Table 3 below. 













2 5.71% 4 11.43%
Diarrhea 1 2.86% 5 14.29
Rash 0 0.00% 1 2.86%
Total 3 8.57% 10 28.58%
3.3 Comparison of Length of Stay between the 
Two Groups
Compared with the control group, the length of stay in the 
observation group was significantly shorter, which was 
statistically signi cant (P<0.05). The details are shown in 
Table 4 below. 
Table 4. Comparison of length of stay between the two 
groups
Grouping Number of people Length of stay (days) 
Observation group 35 5.71±2.01
Control group 35 14.12±1.56
4. Summary 
4.1 Overview of Chronic Atrophic Gastritis 
Chronic atrophic gastritis, a common and frequently dis-
ease of the digestive system, is a chronic gastric disease 
in which the amount of mucosal glandular cells decreases 
or intestinal metaplasia or dysplasia occurs on the basis of 
in ammation of the gastric mucosa. Clinical symptoms in-
cluded abdominal pain, abdominal distension, dyspepsia, 
vomiting, etc. In addition, there are also secretion function 
degeneration, gastric motility insufficiency, poor blood 
circulation, gastric mucous membrane quantity reduction 
etc. According to the professional investigation results of 
relevant personnel, age is one of the major factors leading 
to chronic atrophic gastritis. In addition, the emergence of 
chronic atrophic gastritis is also associated with the fol-
lowing factors: First, genetic factors. Compared with the 
population without family genetic history, the incidence 
of chronic atrophic gastritis in the population with family 
genetic history is relatively higher. According to the rel-
evant data, the specific incidence can reach about 20%. 
Second, anemia. If the body is in the state of ischemia for 
a long time, it will lead to chronic atrophic gastritis. Third, 
direct long-term contact with metals. For those workers 
who have been exposed to lead for a long time, it is very 
easy to damage the gastrointestinal mucosa and develop 
chronic atrophic gastritis. Fourth, dietary habits. People 
who have smoking and drinking habits for a long time are 
more likely to suffer from gastric mucosal damage and 
chronic atrophic gastritis if they take in a large amount of 
stimulating food. Fifth, immune factors. Generally speak-
ing, there are factor antibodies in gastric juice and blood 
of patients with chronic atrophic gastritis. Therefore, the 
immunoreaction of human body is directly related to the 
occurrence of chronic atrophic gastritis. 
4.2 The Necessity and Effect of Clinical Medica-
tion and Treatment 
In the process of sustained and rapid social and econom-
ic development in China, people’s quality of life and liv-
ing standards have been further improved. At the same 
time, people’s dietary habits and dietary structure have 
also undergone tremendous changes, which makes the 
incidence of chronic atrophic gastritis presents a gradu-
ally increasing trend [6]. The so-called chronic atrophic 
gastritis mainly refers to a disease that causes in amma-
tion in the stomach of patients due to the in uence of dif-
ferent factors. This disease is very common in digestive 
internal medicine. The specific clinical manifestations 
include abdominal pain, abdominal distension, dyspep-
sia, vomiting, etc. When suffering from this disease, it is 
likely to further deteriorate into gastric cancer if patients 
do not receive timely and effective treatment, which will 
also pose a threat to the patients’ quality of life, physical 
health and life safety [7]. Xianlu Pazhu Wan is a kind of 
Tibetan medicine pill in Tibetan minority areas of China. 
It is mainly used for the treatment of chronic gastropathy 
in Tibetan areas. The main functions are strengthening 
stomach and dispelling cold, eliminating phlegm, break-
ing tumors and keeping health and strength. It is the 
classic secret recipe of Tibetan medicine for more than 
1000 years after continuous summary of experience, 
scienti c development and inheritance. The prescription 
DOI: https://doi.org/10.30564/jams.v2i4.1118
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contains high purity natural medicines in snow regions at 
an altitude of 6,000 meters. The recipe contains 15 main 
medicines and more than 20 adjuvant medicines, among 
which the main medicinal herb myrobalan has the effect 
of promoting qi, relieving pain and dispelling cold in the 
warm. Pterocephalus hookeri heck has the functions of 
sterilizing, eliminating putridity and engendering  esh. 
Tibetans have applied pterocephalus hookeri heck to 
treat trauma directly. Gypsum rubrum has the functions 
of digestion, acid-making, clearing heat and stomach. 
Neohymenopogon parasiticus can strengthen spleen and 
stomach, regulate qi and relieve depression, relieve cold 
distention, distension and pain, hiccup and other symp-
toms. Xianlu Pazhu Wan contains many bioactive sub-
stances, which can directly target the lesion. Therefore, 
on the basis of conventional western medicine treatment, 
we combined with Xianlu Pazhu Wan to treat chronic 
atrophic gastritis, in order to improve the efficiency of 
treatment and reduce the incidence of adverse effects. 
In the speci c clinical treatment process, we should also 
focus on the following issues: Firstly, the patient’s body 
needs to be thoroughly examined before treatment to 
exclude whether they also have other diseases with oth-
er types of symptoms. Secondly, the patient’s physical 
changes during treatment should be recorded carefully 
and comprehensively, and analyzed and studied, so as to 
provide effective reference for the adjustment of treat-
ment methods. Thirdly, the patient’s disease situation 
and the necessity of treatment should be explained to the 
patients’ family members patiently, improve their coop-
eration in the treatment process, and ensure the smooth 
development and advancement of the treatment work. 
Fourthly, most patients with chronic atrophic gastritis 
have deep roots and are dif cult to be cured completely 
in a short period. Therefore, patients must be treated 
comprehensively in clinical practice, and be told that 
they must take medicine according to doctor’s advice, 
and that they should not stop or change medication at 
will, so as to ensure a good therapeutic effect [8]. 
From the results of this paper, it can be seen that in the 
clinical treatment of chronic atrophic gastritis, compared 
with the control group treated with conventional West-
ern medicine, the observation group treated with Xianlu 
Pazhu Wan on the basis of conventional western medicine 
has better therapeutic effect. The total effective rate of 
treatment is as high as 94.29%, and the observation group 
of patients with H. pylori eradication rate is relatively 
higher, the incidence of adverse effects is only 8.57%, the 
length of stay of patients is relatively shorter, and P is less 
than 0.05, differences were statistically signi cant. 
5. Conclusion
To sum up, in the process of treating chronic atrophic gas-
tritis patients, reasonable and effective treatment methods 
should be determained according to the actual physical 
conditions of patients, and guide patients to adhere to the 
treatment of taking appropriate oral dose of Xianlu Pazhu 
Wan. During the treatment period, the patient must give 
up spicy, strong tea and coffee, smoking and alcohol, and 
keep a light diet. In order to ensure good clinical thera-
peutic effect and improve the treatment ef ciency, reduce 
the incidence of adverse effects, help patients in a shorter 
period to restore health. 
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